Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: A double-blind, placebo-controlled, randomized clinical trial

NeuroImmunoModulation

Volumn 21, Issue 6, 2014, Pages 291-296

  Khalili, Mohammad ^a,b,d   Azimi, Amirreza ^d   Izadi, Vajihe ^g   Eghtesadi, Shahryar ^b   Mirshafiey, Abbas ^c   Sahraian, Mohamad Ali ^e   Motevalian, Abbas ^f   Norouzi, Abbas ^d   Sanoobar, Meisam ^b   Eskandari, Ghazaleh ^d   Farhoudi, Mehdi ^a   Amani, Firouz ^h  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h ARDABIL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokine profile; Inflammatory factors; Lipoic acid; Multiple sclerosis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; INTERLEUKIN 6; PLACEBO; THIOCTIC ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD SAMPLING; BODY MASS; CALORIC INTAKE; COMPARATIVE STUDY; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ADOLESCENT; BLOOD; DIET RESTRICTION; DIET THERAPY; DISABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT; PRACTICE GUIDELINE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIOXIDANTS; CYTOKINES; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FASTING; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; THIOCTIC ACID; YOUNG ADULT;

EID: 84906940699     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000356145     Document Type: Article

References (34)

1. Salinthone S, Yadav V, Schillace RV, Bourdette DN, Carr DW: Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling. PLoS One 2010; 28: 5.
2. Yadav V, Marracci GH, Munar MY, Cherala G, Stuber LE, Alvarez L, et al: Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters. Mult Scler 2010; 16: 387-397.
3. Karg E, Klivényi P, Nemeth I, Bencsik K, Pinter S, Vécsei L: Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 1999; 246: 9-533.
4. Alonso A, Cook SD, Maghzi AH, Divani AA: A case-control study of risk factors for multiple sclerosis in Iran. Mult Scler 2011; 17: 550-555.
5. Jafari N, Hoppenbrouwers IA, Hop WC, Breteler MM, Hintzen RQ: Cigarette smoking and risk of MS in multiplex families. Mult Scler 2009; 15: 1363-1367.
6. Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery S: Shared genetic factors may not explain the raised risk of comorbid inflammatory diseases in multiple sclerosis. Mult Scler 2012; 18: 1430-1436.
7. Ahlgren C, Odén A, Lycke J: High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler 2011; 17: 901-908.
8. Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F: Prevalence of multiple sclerosis in Isfahan, Iran. Neuroepidemiology 2006; 27: 39-44.
9. Moghtaderi A, Rakhshanizadeh F, Shahraki-Ibrahimi S: Incidence and prevalence of multiple sclerosis in southeastern Iran. Clin Neurol Neurosurg 2013; 115: 304-308.
10. Elhami SR, Mohammad K, Sahraian MA, Eftekhar H: A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study. Neuroepidemiology 2011; 36: 141-147.
11. Lauer K: The risk of multiple sclerosis in the USA in relation to sociogeographic features: a factor-analytic study. J Clin Epidemiol 1994; 47: 43-48.
12. Swank RL, Goodwin J: Review of MS patient survival on a Swank low saturated fat diet1. Nutrition 2003; 19: 161-162.
13. Ha H, Lee JH, Kim HN, Kim HM, Kwak HB, Lee S, et al: alpha-Lipoic acid inhibits inflammatory bone resorption by suppressing prostaglandin E2 synthesis. J Immunol 2006; 176: 111-117.
14. Zhang Y, Han P, Wu N, He B, Lu Y, Li S, et al: Amelioration of lipid abnormalities by α-lipoic acid through antioxidative and anti-inflammatory effects. Obesity 2011; 19: 1647-1653.
15. Zhang WJ, Frei B: α-Lipoic acid inhibits TNF- α-induced NF-κB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001; 15: 2423.
16. Sola S, Mir MQS, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, et al: Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome. Circulation 2005; 111: 343-348.
17. Kiemer AK, Müller C, Vollmar AM: Inhibition of LPS-induced nitric oxide and TNF-α production by α-lipoic acid in rat Kupffer cells and in RAW 264.7 murine macrophages. Immunol Cell Biol 2002; 80: 550-557.
18. Yadav V, Marracci G, Lovera J, Woodward W, Bogardus K, Marquardt W, et al: Lipoic acid in multiple sclerosis: a pilot study. Mult Scler 2005; 11: 159-165.
19. Chaudhary P, Marracci GH, Bourdette DN: Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis. J Neuroimmunol 2006; 175: 87-96.
20. Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R, Minghelli S, et al: α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 2004; 148: 146-153.
21. Salinthone S, Schillace RV, Marracci GH, Bourdette DN, Carr DW: Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells. J Neuroimmunol 2008; 199: 46-55.
22. Gallo P, Piccinno MG, Tavolato B, Siden A: A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-[gamma] in multiple sclerosis CSF and serum. J Neurol Sci 1991; 101: 227-232.
23. Sen CK, Roy S, Khanna S, Packer L: Determination of oxidized and reduced lipoic acid using high-performance liquid chromatography and coulometric detection. Methods Enzymol 1999; 299: 239-246.
24. Sook Cho Y, Lee J, Lee TH, Young Lee E, Lee KU, Yeol Park J, et al: α-Lipoic acid inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J Allergy Clin Immunol 2004; 114: 429-435.
25. Ramos LF, Kane J, McMonagle E, Le P, Wu P, Shintani A, et al: Effects of combination tocopherols and alpha lipoic acid therapy on oxidative stress and inflammatory biomarkers in chronic kidney disease. J Renal Nutr 2011; 21: 211-218.
26. Alleva R, Nasole E, Donato FD, Borghi B, Neuzil J, Tomasetti M: alpha-Lipoic acid supplementation inhibits oxidative damage, accelerating chronic wound healing in patients undergoing hyperbaric oxygen therapy. Biochem Biophys Res Commun 2005; 333: 404-410.
27. Imitola J, Chitnis T, Khoury SJ: Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 2005; 106: 163-177.
28. Salinthone S, Yadav V, Schillace RV, Bourdette DN, Carr DW: Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling. PLoS One 2010; 5:e13058.
29. Petereit H, Nolden S, Schoppe S, Bamborschke S, Pukrop R, Heiss WD: Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler 2002; 8: 492-494.
30. Sharief M, Noori M, Ciardi M, Cirelli A, Thompson E: Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-[alpha] and blood-brain barrier damage. J Neuroimmunol 1993; 43: 15-21.
31. Kunt T, Forst T, Wilhelm A, Tritschler H, Pfuetzner A, Harzer O, et al: alpha-Lipoic acid reduces expression of vascular cell adhesion molecule-I and endothelial adhesion of human monocytes after stimulation with advanced glycation end products. Clin Sci 1999; 96: 75-82.
32. Kim HS, Kim HJ, Park KG, Kim YN, Kwon TK, Park JY, et al: Alpha-lipoic acid inhibits matrix metalloproteinase-9 expression by inhibiting NF-kappaB transcriptional activity. Exp Mol Med 2007; 39: 106.
33. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, et al: Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 1997; 94: 590-598.
34. Losy J, Michałowska-Wender G: In vivo effect of interferon-β 1a on interleukin-12 and TGF-β1 cytokines in patients with relapsingremitting multiple sclerosis. Acta Neurol Scand 2002; 106: 44-46.